Major board shake-up at Novo Nordisk amid leadership clash
The Guardian - 21-Oct-2025Wegovy maker faces leadership overhaul after dispute with its largest shareholder
Join the club for FREE to access the whole archive and other member benefits.
Wegovy maker faces leadership overhaul after dispute with its largest shareholder
PP405 shows early promise in reactivating dormant hair follicles to restore growth
Their goal is to make treatments faster, safer, and more effective
Trials showed fewer hospital visits and faster access to care
Partnership aims to uncover disease-driving genes and boost precision drug development
Cirrus Therapeutics targets aging biology to combat blindness from dry AMD
Startup scaled cryopreservation from neural slices to large-animal organs, eyeing human trials
Oura doubles valuation to $10.9B after selling 5.5M rings and projecting $1B+ revenue in 2025
First BioAgent generated 1,000+ hypotheses, raised $900K, and drove lab testing within weeks
Backed by J&J, Carina robot gains traction in China with global approvals on the horizon
Using donated organs, Revalia aims to cut drug failures and speed safe treatments to patients
Funding backs trials of NRG5051, aiming to slow ALS and Parkinson’s by protecting neurons
New funding terms cut early stakes by up to 100-to-1, threatening trust in longevity biotech
Experimental RNAi drug aims to silence alpha-synuclein and slow neurodegeneration
$350K grant fuels Minovia’s biomarker work, as early trials show promising patient gains
Startup uses AI to explore billions of molecules for next-gen skincare innovation
New DeSci platform uses tokens and AI to speed breakthroughs in ageing research
Pharma giant retreats from costly cell therapy deals amid layoffs and R&D cuts
Gordon Sanghera to leave after 20 years as takeover interest grows in UK DNA sequencing firm
New funding will help expand OneSkin’s reach and target ageing at the cellular level
Biotech startup’s valuation soars as it advances de novo protein generation with AI models.
Her focus is on reversing disease through cellular rejuvenation
With $19 million funding, the startup plans regulatory approvals and scaling
The fund bridges East-West collaboration and acts quickly using its own capital
Stentrode lets users control devices with thoughts—implanted via blood vessels, not surgery